Skip to main content

Peer Review reports

From: In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Original Submission
20 Jan 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
27 Jul 2016 Editorially accepted
2 Aug 2016 Article published 10.1186/s12885-016-2635-0

You can find further information about peer review here.

Back to article page